JAZZ Jazz Pharmaceuticals plc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1232524 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY13.5%
TTM net income YoY155.9%
TTM EPS YoY154.9%
Revenue 3-yr CAGR7.5%
Net income 3-yr CAGR37.1%
Margins
Gross margin—
Operating margin9.0%
Net margin4.4%
FCF margin34.4%
EBITDA margin9.8%
Returns
ROE5.1%
ROA1.8%
ROIC (approx.)4.3%
Asset turnover0.40x
Leverage & solvency
Liabilities / assets65.1%
Debt / equity1.33x
Current ratio1.82x
Interest coverage—
Cash quality & payout
Operating cash flow / net income8.22x
Accruals ratio-12.7%
Payout ratio—
Capex / revenue1.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.24B | $1.21B | $1.07B | $1.20B | $1.13B | $1.05B | $897.80M | $1.09B |
| R&D expense | $211.90M | $207.50M | $196.00M | $213.91M | $198.20M | $189.90M | $180.70M | $240.50M |
| SG&A expense | $407.90M | $389.20M | $352.70M | $406.21M | $530.60M | $358.40M | $514.00M | $369.29M |
| Operating income | -$413.40M | $248.20M | $336.60M | $254.53M | $57.50M | -$686.40M | -$55.90M | $190.77M |
| Pretax income | -$458.90M | $211.00M | $299.20M | $208.54M | $9.00M | -$735.60M | -$109.80M | $133.22M |
| Income tax | $24.50M | $18.10M | $6.10M | $4.96M | -$242.40M | -$17.20M | -$17.80M | -$57.91M |
| Net income | -$483.40M | $192.80M | $293.10M | $203.45M | $251.40M | -$718.50M | -$92.50M | $191.12M |
| EBITDA | -$406.30M | $257.30M | $345.70M | $263.94M | $67.40M | -$674.50M | -$45.50M | $200.33M |
| EPS (basic) | -7.48 | 3.05 | 4.73 | — | 4.14 | -11.74 | -1.52 | — |
| EPS (diluted) | -7.48 | 2.78 | 4.43 | — | 4.08 | -11.74 | -1.52 | — |
| Weighted avg. shares (diluted) | 64.70M | 69.40M | 66.10M | — | 61.60M | 61.20M | 61.00M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $2.04B | $1.62B | $1.84B | $1.39B | $1.33B | $1.19B | $1.86B | $2.41B |
| Receivables | $873.70M | $880.90M | $836.30M | $830.70M | $764.36M | $714.00M | $652.99M | $716.76M |
| Inventory | $454.00M | $443.00M | $437.50M | $417.00M | $483.11M | $504.99M | $492.78M | $480.44M |
| Current assets | $4.61B | $3.97B | $4.58B | $4.17B | $3.76B | $3.35B | $4.13B | $4.63B |
| PP&E, net | $224.80M | $212.00M | $203.10M | $199.90M | $188.91M | $184.97M | $178.87M | $173.41M |
| Goodwill | $1.80B | $1.80B | $1.80B | $1.83B | $1.83B | $1.84B | $1.76B | $1.72B |
| Intangibles | $4.17B | $4.03B | $4.20B | $4.43B | $4.57B | $4.77B | $4.72B | $4.76B |
| Total assets | $12.00B | $11.08B | $11.86B | $11.66B | $11.36B | $10.94B | $11.53B | $12.01B |
| Current liabilities | $2.53B | $2.23B | $2.25B | $2.24B | $2.27B | $2.07B | $1.22B | $1.04B |
| Short-term debt | $1.02B | $1.02B | $1.03B | $1.03B | $1.03B | $1.03B | $31.00M | $31.00M |
| Long-term debt | $4.55B | $3.33B | $4.32B | $4.33B | $4.33B | $4.34B | $5.34B | $6.08B |
| Total debt | $5.57B | $4.35B | $5.35B | $5.36B | $5.36B | $5.36B | $5.37B | $6.11B |
| Total liabilities | $7.81B | $6.28B | $7.33B | $7.34B | $7.40B | $7.24B | $7.36B | $7.92B |
| Shareholders' equity | $4.19B | $4.80B | $4.53B | $4.32B | $3.96B | $3.71B | $4.17B | $4.09B |
| Net debt | $3.53B | $2.73B | $3.51B | $3.97B | $4.04B | $4.17B | $3.51B | $3.70B |
| Shares outstanding | — | — | — | 61.44M | — | — | — | 60.63M |
| Cash flow statement | ||||||||
| Operating cash flow | $506.10M | $415.70M | $408.20M | $362.52M | $474.70M | $88.80M | $429.80M | $398.58M |
| Capital expenditure | $16.20M | $18.10M | $19.70M | $16.73M | $15.20M | $12.90M | $13.90M | $13.29M |
| Free cash flow | $489.90M | $397.60M | $388.50M | $345.79M | $459.50M | $75.90M | $415.90M | $385.29M |
| Investing cash flow | -$1.08B | $354.90M | $123.10M | -$372.16M | -$327.80M | -$641.00M | -$169.00M | -$193.29M |
| Financing cash flow | $993.70M | -$994.50M | -$78.50M | $75.44M | -$10.90M | -$124.40M | -$813.50M | -$8.28M |
| Depreciation & amortization | $7.10M | $9.10M | $9.10M | $9.40M | $9.90M | $11.90M | $10.40M | $9.56M |
| Stock-based compensation | $77.20M | $73.30M | $74.50M | $70.85M | $88.10M | $64.50M | $67.70M | $70.19M |
| Share buybacks | $225.00M | — | — | $0 | $0 | — | — | $0 |
Free plan shows the latest 8 periods; Pro shows all 67 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.